Trade AnaptysBio - ANAB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 15.54 |
| Open | 15.8 |
| 1-Year Change | -32.62% |
| Day's Range | 15.67 - 17.01 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 16.80 | 0.85 | 5.33% | 15.95 | 17.05 | 15.61 |
| Jan 17, 2025 | 15.79 | 0.84 | 5.62% | 14.95 | 16.14 | 14.95 |
| Jan 16, 2025 | 14.96 | -0.37 | -2.41% | 15.33 | 15.47 | 14.70 |
| Jan 15, 2025 | 15.43 | 0.23 | 1.51% | 15.20 | 15.46 | 14.76 |
| Jan 14, 2025 | 14.85 | 0.60 | 4.21% | 14.25 | 15.43 | 14.20 |
| Jan 13, 2025 | 14.56 | 0.60 | 4.30% | 13.96 | 14.61 | 13.45 |
| Jan 10, 2025 | 14.19 | 0.50 | 3.65% | 13.69 | 14.21 | 13.56 |
| Jan 8, 2025 | 14.31 | -0.21 | -1.45% | 14.52 | 14.95 | 13.96 |
| Jan 7, 2025 | 14.77 | -0.41 | -2.70% | 15.18 | 15.38 | 14.56 |
| Jan 6, 2025 | 15.22 | 0.71 | 4.89% | 14.51 | 15.88 | 14.24 |
| Jan 3, 2025 | 14.50 | 0.52 | 3.72% | 13.98 | 14.70 | 13.68 |
| Jan 2, 2025 | 13.29 | 0.36 | 2.78% | 12.93 | 13.42 | 12.71 |
| Dec 31, 2024 | 13.18 | 0.37 | 2.89% | 12.81 | 13.49 | 12.76 |
| Dec 30, 2024 | 13.17 | 0.36 | 2.81% | 12.81 | 13.26 | 12.40 |
| Dec 27, 2024 | 12.97 | -0.51 | -3.78% | 13.48 | 13.62 | 12.90 |
| Dec 26, 2024 | 13.66 | 0.03 | 0.22% | 13.63 | 14.21 | 13.55 |
| Dec 24, 2024 | 13.80 | -0.03 | -0.22% | 13.83 | 14.41 | 13.77 |
| Dec 23, 2024 | 13.89 | -0.27 | -1.91% | 14.16 | 14.63 | 13.84 |
| Dec 20, 2024 | 14.46 | -0.01 | -0.07% | 14.47 | 15.06 | 14.04 |
| Dec 19, 2024 | 14.92 | -0.14 | -0.93% | 15.06 | 15.27 | 14.45 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
AnaptysBio Company profile
About AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, AnaptysBio Inc revenues decreased 16% to $63.2M. Net loss increased from $19.9M to $57.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 22% to $92.6M (expense), Interest income decrease of 89% to $431K (income).
| Industry: | Bio Therapeutic Drugs |
10770 Wateridge Circle, Suite 210
SAN DIEGO
CALIFORNIA 92121
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com